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ORIGINAL ARTICLE
Chest wall sarcoma: outcome in 22 patients after resection requiring
thoracic cage reconstruction
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Abstract
Purpose. To evaluate the outcome after resection of malignant chest wall sarcoma, requiring reconstruction of the chest
wall.
Subjects. Twenty-two patients, 15 with primary tumours, were operated on in our institution between 1983 and 1996.
Four patients underwent surgery after a previous intralesional or marginal excision and three patients because of a local
recurrence.
Methods. The tumour was resected `en bloc’, including skin, muscle and thoracic skeleton. When necessary, adjacent
organs invaded by the tumour, such as lung, pericardium and diaphragm, were also removed to obtain a wide margin.
Reconstruction of the chest wall was performed with Marlex mesh (n 5 9), methylmethacrylate cement (n 5 2) or a Marlex
methylmethacrylate `sandwich’ (n 5 11).
Results. The median tumour size was 9.5 (2± 20) cm. The most common type of tumour was chondrosarcoma (12 cases).
No patient died in hospital. Five patients required reoperation because of complications, two patients because of loosening
of the acrylate prosthesis, two because of necrosis of soft tissue coverage and one was reoperated because of bleeding. Four
patients died of generalized tumour disease between 5 and 77 months after surgery and one patient died of a local
recurrence 32 months after the primary operation. Seventeen patients are alive, with a median follow-up of 36 (4± 162)
months. Microscopic radicality (negative margin) was achieved in 17 patients but 5 of these had local recurrences. Two
of ® ve patients with positive margins had a local recurrence of the tumour. Of the seven patients with local recurrences,
two also developed metastases.
Discussion. Large chest wall sarcomas can be successfully resected and the chest wall reconstructed with low morbidity
and mortality.
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Introduction
In recent years, successful surgery has been reported
even for advanced malignant chest wall tumours.
Five-year survival rates between 20 and 90%
1± 5 and
local recurrence rates of 15± 40%
3,6 have been
achieved. The key to good long-term results seems
to be extensive resection with a wide margin.
Aggressive surgery is possible if chest wall repair
affords enough stability and airtight closure. This
may be obtained by reconstructing the thoracic cage
with synthetic materials and appropriate soft tissue
coverage, often with myo-cutaneous ¯ aps. The pre-
sent study reviews our experience with the surgical
management of chest wall sarcoma requiring recon-
struction of chest wall defects.
Subjects and methods
Our University Hospital is a tertiary referral centre
for patients with musculoskeletal tumours and
serves about 1.5 million inhabitants. Between 1983
and 1996, we operated on 22 patients (13 men, 9
women) for primary or locally recurrent chest wall
sarcoma requiring reconstruction of the chest wall.
Patients with small sarcomas, where resection could
be performed without chest wall repair, are
excluded. The patients had a median age of 51
(16± 82) years at the time of surgery. Diagnostic
needle or incisional biopsy of the lesion was per-
formed in all patients who had not previously under-
gone surgery, except patient no. 19. This patient
had Mb Ollier and the diagnosis of secondary chon-
drosarcoma was obvious. Fourteen patients had a
primary skeletal sarcoma and eight had a soft tissue
sarcoma. The most common type of tumour was
chondrosarcoma (12 cases). Two patients (nos. 5
and 21) developed a sarcoma at the site of previous
tissue irradiation, having had a mastectomy 7 and
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14 years earlier. Seven patients had undergone lim-
ited intralesional or marginal local surgery in other
institutions before referral. Three of them were
referred for extended resection shortly after surgery,
while the other four were referred after detection of
a local recurrence. Three patients (with Ewing’s
sarcoma, osteosarcoma and malignant ® brous histi-
ocytoma, respectively) received preoperative chemo-
therapy.
Preoperative evaluation of the tumour included
chest roentgenography, computed tomography and,
more recently, magnetic resonance imaging in four
cases. Respiratory function was assessed with
spirometry and, if needed, ventilation and perfusion
scans and blood gases. Surgery was performed as a
one-stage procedure. Profylactic antibiotic,
cefuroxim, was administered prior to surgery. The
tumour was resected `en bloc’, including skin, muscle
and thoracic skeleton, with an intended macroscopic
tumour-free cuff. One normal rib above and one
below the most cranial and caudal tumour extension
were included in the specimen. In selected cases,
resection included parts of the lung, the peri-
cardium, the diaphragm and the abdominal wall. In
two cases, the arm had to be sacri® ced by a fore-
quarter amputation. Depending on the location and
size of the resected chest wall, reconstruction was
performed with Marlex mesh or a Marlex methyl-
methacrylate `sandwich’. Non-absorbable sutures of
heavy calibre were used for ® xation but for the
sternum where stainless steel sutures were applied.
If possible, soft tissue was closed per primum, other-
wise myo-cutaneous ¯ aps were used, in some cases
with additional skin grafting. Two (nos. 4 and 14) of
the ® ve patients who did not obtain tumour-free
margins were given postoperative radiotherapy.
All patients were followed regularly with a physi-
cal examination and chest radiographs. The median
duration of follow-up for the surviving 17 patients is
36 (4± 162) months.
Results
The results are shown in Table 1. The median
hospital stay was 9 (4± 55) days. There was no
perioperative mortality.
Five patients were reoperated because of compli-
cations. In two cases (patient nos. 5 and 6), the
Marlex methylmethacrylate `sandwich’ loosened,
due to ruptured sutures between the prosthesis and
the ribs. The younger patient moved a great deal
while awakening from the anaesthesia, which may
have caused the loosening. She was reoperated on
after 20 days and a new Marlex methylmethacrylate
`sandwich’ was applied. The other patient also
showed signs of early loosening of the prosthesis.
Part of the circumference of this prosthesis was
sutured to abdominal muscles. A conservative
regime was chosen because of the patient’s old age.
However, skin and soft tissue necrosis developed
and was followed by an infection. The prosthesis
was removed and the infection healed. No recon-
structive surgery has since been carried out and the
patient now has an abdominal hernia, with mild
discomfort.
Two patients developed soft tissue necrosis over
the prosthesis after about two weeks. One patient
(no. 21) required surgery in irradiated tissue (14
years after treatment for breast cancer) and was
successfully reoperated with a myo-cutaneous rectus
abdominis ¯ ap. The other patient (no. 18) with a
generalized malignancy underwent a palliative pri-
mary resection due to a huge chest wall chondrosar-
coma, causing severe symptoms and was reoperated
with a new fascio-cutaneous ¯ ap, without further
local complications.
Patient no. 17 (our ® rst patient) was reoperated
during the ® rst postoperative night because of a
haemorrhage. The source of bleeding was the left
ventricle of the heart, where the acrylate prosthesis
came in contact with the epicardium, causing an
effect like sandpaper, since the pericardium had
been removed en bloc with the tumour. The great
omentum was interposed to remedy this.
Seven patients developed local recurrences, all
con® rmed by tissue samples, and 5 of these (nos.
8,12,19,21 and 22) were reoperated. Patient no. 8 is
disease-free 9 months after the second operation
and patient no. 12 after 78 months.
Five patients had metastases. Three of these had
pulmonary metastases diagnosed already at the time
of surgery. One patient (no. 5) is now being treated
with chemotherapy but the other four have died.
Five patients (nos. 18± 22) died of their malignan-
cies between 5 and 77 months after the operation.
Patient no. 21 died after a local recurrence and the
other four because of metastatic disease. Another
patient (no. 4) died in a car accident, with no
detectable disease.
Discussion
Sarcoma of the chest wall presents a therapeutic
dilemma, if allowed to become large prior to
surgery. A tumour-free margin for a chest wall sar-
coma may require resection of several ribs and
adjacent soft tissue and efforts must be made to
restore chest wall stability and function. Reconstruc-
tion is essential for large anterior and lateral defects
to prevent paradoxical respiration, but is generally
not required for defects in the thoracic apex or
sub-scapular region. A rigid chest wall prosthesis is
important for preserving pulmonary function.
3,7
This makes early extubation possible and shortens
hospitalization.
5,7 Myo-cutaneous ¯ aps can be used
without rigid support, but the risk of prolonging
postoperative ventilatory support increases.
7 These
¯ aps may also become more ¯ accid with time.
Many synthetic and biological materials have
been used over the years, including Marlex mesh,Chest wall sarcoma 145
Table 1. Patient data
Age
Pat. (years) Sex Operation Resected tissue
1 18 m primary costae VII± IX, pulmonary wedge
2 51 f primary costae V± VIII, part of sternum
3 45 f recurrent clavicle, costa I, part of sternum
4 24 m primary costae I± II
5 61 f primary costae III± VI
6 82 m primary costae VII± IX, part of diaphragm
7 47 m primary costae IV± VI, part of sternum
8 40 f extended costae Vl± VIII
9 34 m extended costae II± IV
10 65 m primary costa IV
11 38 f primary costae II± IV, part of sternum
12 38 m primary costae III± V
13 54 f recurrent sternum
14 16 m primary costa IV
15 74 f primary costae IV± VI
16 77 f extended costae VII± VIII
17 56 m primary part of sternum
18 67 m recurrent sternum, costal arci
19 51 m primary c. IV± IX, peric., diaphr., abd. wall, pulm. wedge
20 39 m recurrent fqa, muscle overpreviously resected ribs
21 66 f primary fqa, c. II± IV, part of sternum
22 51 m primary costal X± XI, part of diaphragm
Tumour
Pat. Reconstruction Soft tissue coverage Type of sarcomaÐ grade size (cm)
1 acrylate/marlex direct closure osteosarcomaÐ H 10
2 acrylate direct closure malignant schwannomaÐ H 4
3 marlex direct closure chondrosarcomaÐ L 4
4 marlex direct closure spindle cell sarcomaÐ H 10
5 acrylate/marlex m. latissimus ¯ ap1 skin graft spindle cell sarcomaÐ H 8
6 acrylate direct closure chondrosarcomaÐ H 9
7 acrylate/marlex direct closure chondrosarcomaÐ H 6
8 acrylate/marlex direct closure synovial sarcomaÐ H 10
9 acrylate/marlex direct closure malignant schwannomaÐ L 20
10 marlex direct closure chondrosarcomaÐ L 3
11 acrylate/marlex direct closure chondrosarcomaÐ H 9
12 marlex direct closure chondrosarcomaÐ H 12
13 acylate/marlex direct closure chondrosarcomaÐ L 2
14 marlex direct closure Ewing’s sarcomaÐ H 9
15 marlex direct closure chondrosarcomaÐ L 7
16 marlex direct closure liposarcomaÐ H 5
17 acrylate/marlex myo-cutaneous ¯ ap chondrosarcomaÐ H 13
18 marlex myo-cutaneous ¯ ap 1 skin graft chondrosarcomaÐ H 10
19 acrylate/marlex/Goretex m. latissimus ¯ ap1 skin graft chondrosarcomaÐ H 20
20 acrylate/marlex cutaneous ¯ ap ® brosarcomaÐ H 12
21 acrylate/marlex cutaneous ¯ ap malign. ® brous histiocytomaÐ H 12
22 marlex direct closure chondrosarcomaÐ H 13
methylmethacrylate, Goretex, Vicryl, bone, metal,
fascia and dehydrated human dura.
3,9± 13 Some have
been abandonedÐ for example, fascia lata, due to a
tendency to become ¯ accid with time.
11 We used
Marlex mesh or a stiff prosthesis made of methyl-
methacrylate (bone cement). Methylmethacrylate
sandwiched between two layers of Marlex mesh
weighs little and is versatile, bonds ® rmly to bone,
allows tissue in-growth, and is radiolucent for sub-
sequent lung-® eld evaluation.
10 In our hands, bone
cement was of particular value when an arched
prosthesis for the lateral thoracic wall was required.
We have had two cases of loosening of the pros-
thesis. Stable anchorage to the ribs or sternum is
obviously important. We have preferred to limit the
size of the prosthesis to prevent the edge of the146 P. Jo È nsson et al.
Table 1. Patient dataÐ continued
Tumour-free Hospital Follow-up Local recurrence Metastasis
Pat. margin stay (days) (months) (months) (months)
1 yes 5 4
2 yes 7 7
3 yes 7 11
4 no 6 12
5 yes 55 17 12 12
6 yes 12 19
7 yes 6 24
8 yes 4 32 23
9 yes 9 36
10 yes 6 70
11 yes 10 111
12 yes 11 120 43
13 yes 28 121
14 no 9 126
15 yes 7 127
16 yes 7 127
17 yes 25 162
18 no 21 5* 0
19 no 20 13* 6 0
20 yes 27 25* 12 12
21 yes 38 32* 5
22 no 7 77* 31 0
Pat.5 patient number; age5 age at the time of surgery; f 5 female; m 5 male; pri-
mary 5 previously not operated; extended 5 reoperation of primary tumour; previous operation
considered not radical; recurrent5 local recurrent sarcoma; reconstruction 5 type of prosthesis
used; fqa 5 fore-quarter amputation; Goretex used to replace resected diaphragm; H 5 high-
grade sarcoma; L 5 low-grade sarcoma; tumour size: largest diameter; follow-up: last® ve patients
deceased*; metastasis 0 5 metastasis present at time of surgery.
prosthesis from riding on an edge of the rib or
sternum.
Infection of the prosthesis might be a problem.
6
An overall wound infection rate of about 5% has
been reported by several authors. If the soft tissue,
overlying the prosthesis, is inadequately vascular-
ized, the infection rates increases.
5,10,14 We experi-
enced only one patient with infection and this
occurred after soft tissue necrosis secondary to the
pressure of a loose prosthesis. We have used gen-
tamicin in the cement which may have had a posi-
tive effect.
It is often possible to create soft tissue coverage,
by direct closure or by using local myo-cutaneous
¯ aps. Primary closure was done in 16 of our patients
having deep-seated tumours with no involvement of
the skin. However, in some cases, with large defects
or damaged tissue due to prior radiation therapy,
more distant muscle must be transposed.
15 We had
one case with necrosis of the myo-cutaneous ¯ ap in
tissue previously radiated because of breast cancer.
This patient healed after a reoperation with transpo-
sition of the rectus abdominis muscle.
Five patients had positive microscopic margins
and two of them developed local recurrences. Three
of the ® ve patients died during follow-up because of
their malignancies and another patient was killed in
a car accident one year after the operation, without
known recurrent disease. The ® fth patient, with
Ewing’s sarcoma, received adjuvant chemotherapy
and is free from malignant disease, more than 10
years after surgery. Different combinations of
surgery, chemotherapy and radiotherapy are
employed for musculoskeletal sarcomas. Osteosar-
coma (including malignant ® brous histiocytoma of
bone) and Ewing’s sarcoma are commonly treated
by preoperative and postoperative chemotherapy
whereas chemotherapy for soft tissue sarcomas is
controversial.
16 Local radiotherapy, pre- or postop-
eratively, reduces the local recurrence risk especially
when there is tumour in the resection border. The
only independent poor-risk factor known to cause a
local recurrence is incomplete tumour resection.
4,17
Distant metastases of chondrosarcoma occur in one
third of patients who develop local recurrences, but
in only 4% of those without local recurrences.
18
Our results provide evidence that a large malig-
nant tumour of the chest wall can be successfully
managed with low morbidity and mortality by wide
excision and reconstruction of the chest wall.
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